Spectral AI Submits De Novo 510k Application to FDA for Innovative DeepView® System with Federal Support

Reuters

2025/06/30

Spectral AI Submits De Novo 510k Application to FDA for Innovative DeepView® System with Federal Support

DALLAS, June 30, 2025 - Spectral AI $(MDAI)$, a leader in AI-driven medical diagnostics, announced the submission of its De Novo 510k marketing clearance application to the U.S. Food and Drug Administration (FDA) for its innovative DeepView® System. This submission marks a significant milestone for Spectral AI as it seeks to bring its novel burn care diagnostic device to the U.S. market. The DeepView System, which received Breakthrough Device Designation from the FDA in 2018, leverages multi-spectral imaging and AI algorithms to assess burn healing potential, providing clinicians with immediate, data-driven insights to enhance patient care. The development and regulatory efforts for this technology have been supported by federal funds from the U.S. Department of Health and Human Services, Administration for Strategic Preparedness and Response, and BARDA under multiple contracts with Spectral MD, Inc., a wholly-owned subsidiary of Spectral AI.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spectral Ai Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9486416-en) on June 30, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2547099875"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2547099875\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2547099875?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-30 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2547099875","market":"fut","top_or_hot":-1,"title":"Spectral AI Submits De Novo 510k Application to FDA for Innovative DeepView® System with Federal Support","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Spectral AI Submits De Novo 510k Application to FDA for Innovative DeepView® System with Federal Support\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        DALLAS, June 30, 2025 - Spectral AI <a href=\"https://laohu8.com/S/MDAI\">$(MDAI)$</a>, a leader in AI-driven medical diagnostics, announced the submission of its De Novo 510k marketing clearance application to the U.S. Food and Drug Administration (FDA) for its innovative DeepView® System. This submission marks a significant milestone for Spectral AI as it seeks to bring its novel burn care diagnostic device to the U.S. market. The DeepView System, which received Breakthrough Device Designation from the FDA in 2018, leverages multi-spectral imaging and AI algorithms to assess burn healing potential, providing clinicians with immediate, data-driven insights to enhance patient care. The development and regulatory efforts for this technology have been supported by federal funds from the U.S. Department of Health and Human Services, Administration for Strategic Preparedness and Response, and BARDA under multiple contracts with Spectral MD, Inc., a wholly-owned subsidiary of Spectral AI.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spectral Ai Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9486416-en) on June 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Spectral AI Submits De Novo 510k Application to FDA for Innovative DeepView® System with Federal Support</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSpectral AI Submits De Novo 510k Application to FDA for Innovative DeepView® System with Federal Support\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-30 20:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Spectral AI Submits De Novo 510k Application to FDA for Innovative DeepView® System with Federal Support\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        DALLAS, June 30, 2025 - Spectral AI <a href=\"https://laohu8.com/S/MDAI\">$(MDAI)$</a>, a leader in AI-driven medical diagnostics, announced the submission of its De Novo 510k marketing clearance application to the U.S. Food and Drug Administration (FDA) for its innovative DeepView® System. This submission marks a significant milestone for Spectral AI as it seeks to bring its novel burn care diagnostic device to the U.S. market. The DeepView System, which received Breakthrough Device Designation from the FDA in 2018, leverages multi-spectral imaging and AI algorithms to assess burn healing potential, providing clinicians with immediate, data-driven insights to enhance patient care. The development and regulatory efforts for this technology have been supported by federal funds from the U.S. Department of Health and Human Services, Administration for Strategic Preparedness and Response, and BARDA under multiple contracts with Spectral MD, Inc., a wholly-owned subsidiary of Spectral AI.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spectral Ai Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9486416-en) on June 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票月供概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nNDL9gHjkJ:1","article_id":"2547099875","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2547099875","pubTimestamp":1751284835,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"DALLAS, June 30, 2025 - Spectral AI , a leader in AI-driven medical diagnostics, announced the submission of its De Novo 510k marketing clearance application to the U.S. Food and Drug Administration  for its innovative DeepView System. This submission marks a significant milestone for Spectral AI as it seeks to bring its novel burn care diagnostic device to the U.S. market. The DeepView System, which received Breakthrough Device Designation from the FDA in 2018, leverages multi-spectral imaging and AI algorithms to assess burn healing potential, providing clinicians with immediate, data-driven insights to enhance patient care. The development and regulatory efforts for this technology have been supported by federal funds from the U.S. Department of Health and Human Services, Administration for Strategic Preparedness and Response, and BARDA under multiple contracts with Spectral MD, Inc., a wholly-owned subsidiary of Spectral AI.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","NDAQ":"纳斯达克OMX交易所","BK4112":"金融交易所和数据","MDAI":"Spectral AI Inc.","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4082":"医疗保健设备","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4588":"碎股"},"translate_title":"Spectral AI向FDA提交创新DeepView的从头510k申请®有联邦支持的系统","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"MDAI":0.9},"content_text":"Spectral AI Submits De Novo 510k Application to FDA for Innovative DeepView® System with Federal Support\n    \n\n        DALLAS, June 30, 2025 - Spectral AI $(MDAI)$, a leader in AI-driven medical diagnostics, announced the submission of its De Novo 510k marketing clearance application to the U.S. Food and Drug Administration (FDA) for its innovative DeepView® System. This submission marks a significant milestone for Spectral AI as it seeks to bring its novel burn care diagnostic device to the U.S. market. The DeepView System, which received Breakthrough Device Designation from the FDA in 2018, leverages multi-spectral imaging and AI algorithms to assess burn healing potential, providing clinicians with immediate, data-driven insights to enhance patient care. The development and regulatory efforts for this technology have been supported by federal funds from the U.S. Department of Health and Human Services, Administration for Strategic Preparedness and Response, and BARDA under multiple contracts with Spectral MD, Inc., a wholly-owned subsidiary of Spectral AI.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spectral Ai Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9486416-en) on June 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}